Ad Scientiam develop reliable solutions to measure disease evolution to accelerate treatment decisions to fight the disabilities.
Ad Scientiam has raised $5.7M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in November 2025.
Ad Scientiam's investors include Bedex et Associés, BIODIGITAL PARTICIPATIONS, Techlife Capital.
Ad Scientiam is headquartered in Paris, France.
Ad Scientiam develop reliable solutions to measure disease evolution to accelerate treatment decisions to fight the disabilities.
Ad Scientiam is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ad Scientiam — Funding & Investors." VCBacked, November 5, 2025, https://www.vcbacked.co/company/ad-scientiam. Accessed July 20, 2026.
VCBacked. (2025). Ad Scientiam — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/ad-scientiam
{{cite web |title=Ad Scientiam — Funding & Investors |url=https://www.vcbacked.co/company/ad-scientiam |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated